thinkstockMay 29, 2014: Markets opened higher on Thursday following reports that U.S. GDP contracted by 1% in the first quarter and that new claims for jobless benefits fell to 300,000. Pending home…
Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance is that Pfizer may now simply be having an identity crisis.
thinkstockMay 8, 2014: Markets opened lower on Thursday and posted solid gains on a good report on new claims for jobless benefits. Momentum stocks lost their get-up-and-go in the afternoon, though, and…
These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, May 8, 2014. They include Chevron, Exxon, FedEx, Merck, Tesla, Twitter, Disney and Yelp.
thinkstockMay 6, 2014: Markets opened lower on Monday and sank slowly and surely for the rest of the day. The dollar weakened against the yen overnight removing some enthusiasm for risk in…
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
This past week brought yet another swing taking the Dow Jones Industrial Average to within 30 points or so of an all-time record high. 24/7 Wall St, wanted to review the four…
Endocyte and Merck have terminated their joint late-stage study of an ovarian cancer treatment after the trials failed to show results. Endocyte expressed surprise at the recommendation to halt the trial.
Paul Ausick These are the top analyst upgrades, downgrades and initiations from Wall Street on Wednesday, April 30, 2014. They include ARM Holdings, Coach, Merck, Netflix, Sprint, 3D Systems and Twitter.
thinkstockApril 29, 2014: Markets opened higher on Tuesday getting a boost from energy and biotech stocks right at the start of trading. Economic data was both sparse and not supportive, with the…
Merck & Co. reported mixed first-quarter 2014 results before markets opened Tuesday morning. The loss of market exclusivity continues to hurt the top line. Merck reaffirmed its forecast for the full year.
Paul Ausick The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it…
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of…
Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for the full year.
Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance also allowed sellers to keep exiting the…
